Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
limantrafin (CB-103) / Cellestia Biotech
CAILA, NCT04714619: CB-103 Plus NSAI In Luminal Advanced Breast Cancer	Terminated	2	2	Europe	CB-103, Letrozole, Anastrozole	MedSIR, Cellestia Biotech AG	Advanced Breast Cancer	09/21	04/22
NCT05464836: Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL	Terminated	2	2	US	CB-103, Cellestia, Venetoclax, ABT-199	M.D. Anderson Cancer Center	Leukemia, Lymphoblastic, Leukemia	08/24	08/24
NCT03422679 / 2017-001491-35: Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies	Terminated	1/2	79	Europe, US, RoW	CB-103	Cellestia Biotech AG	Breast Cancer, Colorectal Cancer, Adenoid Cystic Carcinoma, Non-hodgkin Lymphoma, Glomus Tumor, Malignant, Hepatocellular Carcinoma, Osteosarcoma, T-ALL	11/22	11/22
NCT05774899: CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC	Active, not recruiting	1/2	10	US	CB-103, Abemaciclib, Lenvatinib, Lenvima	Glenn J. Hanna, Adenoid Cystic Carcinoma Research Foundation, Cellestia Biotech AG	Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Carcinoma, Recurrent Adenoid Cystic Carcinoma	06/25	06/26